Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injection solution for intravenous use. It enhances magnetic resonance imaging of the brain, spine, abdomen, cardiovascular system and other regions in patients requiring diagnostic contrast enhancement.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide.

Multihance (gadobenate dimeglumine) is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of various anatomical regions.

- Brain and central nervous system MRI: provides enhanced delineation of lesions and vascular structures. - Spine MRI: improves contrast between spinal cord, vertebral bodies and surrounding tissues. - Liver and abdominal MRI: highlights hepatic lesions and vascular anatomy. - Cardiovascular MRI and MR angiography: enhances visualization of cardiac chambers, vessels and perfusion. - Contrast‑enhanced magnetic resonance angiography: facilitates detailed arterial mapping.

Multihance may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient discomfort after injection. - Injection site discomfort: pain or burning at the infusion site. - Warmth sensation: brief feeling of heat during administration. - Dizziness: light‑headedness that resolves quickly.

Serious or Rare Side Effects: - Allergic reactions: including anaphylaxis, requiring immediate medical attention. - Nephrogenic systemic fibrosis (NSF): rare but severe condition in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure. - Cardiac arrest: extremely rare, may occur in hypersensitive individuals. - Pulmonary edema: fluid accumulation in the lungs, requiring urgent care.

Before administering Multihance, consider the following safety measures.

- Renal function assessment: evaluate glomerular filtration rate to identify patients at risk for NSF. - Pregnancy: Category C; use only if the diagnostic benefit outweighs potential fetal risk. - Allergy history: screen for prior reactions to gadolinium‑based agents or other contrast media. - Concurrent nephrotoxic drugs: monitor renal status when used with agents such as aminoglycosides. - Dosage adjustment: follow prescribing information; no routine dose changes are required. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other medicines or clinical conditions; awareness helps mitigate risk.

Major Interactions (Avoid): - Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid use. - Concurrent high‑dose iodinated contrast agents: may amplify nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect renal clearance; monitor kidney function. - Nephrotoxic antibiotics (e.g., aminoglycosides): increase renal risk; observe renal parameters. - Metformin: consider temporary discontinuation in patients with compromised renal function.